Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 72.17$. Average daily volumn in 3 months 9.64M. Market cap 150.98B

Stock symbol : BMY. Exchange : NYSE. Currency : USD
Lastest price : 70.71$. Total volume : 8.19M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Bristol-Myers Squibb Company (BMY)
Last Price

Previous Close71.29
Day Range70.13-71.37
Bid70.72 x 1k
Ask71.49 x 900
Average Volume9.64M
Market Cap150.98B
52 Week Range53.22-80.59
Trailing P/E23.49
Foward P/E8.83
Dividend (Yield %)3.03%
Ex-Dividend Date2022-10-06

Financial Details

According to Bristol-Myers Squibb Company's financial reports the company's revenue in 2021 were 46.38B an increase( +9.52%) over the years 2020 revenue that were of 42.52B. In 2021 the company's total earnings were 6.99B while total earnings in 2020 were -9.02B(-166.67%).

Loading ...


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi... cations; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Market Cap:
Total Assets:
Total Cash:

News about "Bristol-Myers Squibb Company"


With 78% ownership of the shares, Bristol-Myers Squibb Company (NYSE:BMY) is heavily dominated by institutional owners

Source from : YAHOO!Finance - 12 hours ago

If you want to know who really controls Bristol-Myers Squibb Company ( NYSE:BMY ), then you'll have to look at ...See details»


What Bristol-Myers Squibb Company's (NYSE:BMY) ROE Can Tell Us

Source from : Nasdaq - 3 days ago

We'll use ROE to examine Bristol-Myers Squibb Company (NYSE:BMY), by way of a worked example. Return on equity or ROE is a key measure used to assess how efficiently a company's management is ...See details»

Bristol Myers Squibb (BMY) Stock Moves -0.81%: What You Should Know

Source from : YAHOO!Finance - 1 days ago

Bristol Myers Squibb (BMY) closed the most recent trading day at $70.71, moving -0.81% from the previous trading session.See details»


Giovanni Caforio Sells 25,000 Shares of Bristol-Myers Squibb (NYSE:BMY) Stock

Source from : Defense World - 15 hours ago

CEO Giovanni Caforio sold 25,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $69.71, for a total value of $1,742,750.00.See details»


Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Increased by Allworth Financial LP

Source from : Defense World - 1 days ago

Allworth Financial LP lifted its stake in Bristol-Myers Squibb (NYSE:BMY โ€“ Get Rating) by 15.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange ...See details»


Bristol Myers Squibb Is a Must-Own Stock Right Now. Here's Why.

Source from : The Motley Fool on MSN - 12 days ago

This blue chip big pharma stock offers investors a recession-proof business, a rising top line, and a solid dividend.See details»

Bristol-Myers Squibb, Cash, Cheniere Energy And This Tech Company Are CNBC's Final Trades

Source from : on MSN - 1 days ago

On CNBCโ€™s โ€œHalftime Report Final Trades,โ€ Jim Lebenthal of Cerity Partners said Bristol-Myers Squibb Co (NYSE: BMY) has a โ€œgood dividend yieldโ€ and is a &l ...See details»

Why Bristol Myers Squibb Stock Bounced Higher Today

Source from : Nasdaq - 2 days ago

Shares of Bristol Myers Squibb were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week. The big drugmaker didnt reportany ...See details»

Is Bristol-Myers Squibb Company's (NYSE:BMY) ROE Of 20% Impressive?

Source from : Yahoo - 4 days ago

To keep the lesson grounded in practicality, we'll use ROE to better understand Bristol-Myers Squibb Company (NYSE:BMY). Return on equity or ROE is a key measure used to assess how efficiently a ...See details»

BMY Bristol-Myers Squibb Company

Source from : Seeking Alpha - 3 days ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»

Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock

Source from : on MSN - 1 days ago

The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades.See details»

Berenberg downgrades Bristol-Myers Squibb, says upside is running out

Source from : CNBC - 10 days ago

Bristol-Myers Squibb shares are running out of room to run after surging nearly 14% year to date, Berenberg said. The group on Tuesday downgraded shares of the pharmaceutical company to hold from ...See details»

Bristol Myers Squibb Shakes Up Key Biotech Battleground

Source from : MSN - 10 days ago

Bristol Myers Squibb (BMY) - Get Bristol-Myers Squibb Company Report certainly did. The $150 billion drug developer enjoyed a 6% pop after announcing FDA approval for one of its closely-watched ...See details»

Is Most-Watched Stock Bristol Myers Squibb Company (BMY) Worth Betting on Now?

Source from : AOL - 11 days ago

Bristol Myers Squibb (BMY) is one of the stocks most watched ... Over the past month, shares of this biopharmaceutical company have returned -2.9%, compared to the Zacks S&P 500 composite's ...See details»